Is Vivos Therapeutics Inc (VVOS) overvalued? · rev $15.0M
Vivos Therapeutics Inc (VVOS) is a medical devices company listed on NASDAQ.
This page asks whether Vivos Therapeutics Inc (VVOS) looks expensive on cached numbers — not a short thesis.
Latest reported VVOS revenue for 2024-12-31 was $15.0M. Net income was -$11.1M. Revenue was up 8.9% from 2023-12-31 to 2024-12-31. VVOS currently screens at market cap $7.1M.
VVOS currently screens at market cap $7.1M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next VVOS 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the VVOS stock page for the full model, not this heading.
Not investment advice.